未经授权:TMEM59L是一种新发现的跨膜蛋白;其在癌症中的功能仍然未知。本研究旨在揭示TMEM59L在癌症中的预后价值和功能作用。
未经批准:基因表达谱,甲基化数据,从癌症基因组图谱(TCGA)和基因型-组织表达数据库检索TMEM59L的相应临床数据。采用生存分析来计算TMEM59L的泛癌症预后价值。TMEM59L表达与肿瘤免疫微环境、基于TCGA的数据,评估了不同癌症的DNA甲基化动态和基因组异质性.
UNASSIGNED:我们的发现表明,在不同癌症类型中观察到TMEM59LmRNA表达的明显差异,并且在晚期病理阶段观察到较高的TMEM59L表达,并且与肾肾乳头状细胞癌的预后较差有关。膀胱尿路上皮癌,结肠腺癌,肾透明细胞癌.通路分析表明,TMEM59L在癌症发展以及免疫和癌症相关通路如上皮-间质转化和TGF-β信号传导中发挥了关键影响。此外,相关分析表明TMEM59L表达与CD8T细胞呈负相关,活化的CD4T细胞,和几个免疫调节剂,包括IDO1,TIGIT,各种癌症中的PD-L1、CTLA-4和BTLA。生存分析表明,TMEM59L基因的高甲基化与更长的生存时间有关。在TMEM59L表达和免疫表型之间也观察到显着的相关性,同源重组缺陷,杂合性丢失,肿瘤干性评分,和各种癌症中的新抗原。重要的是,我们还确定了许多可能靶向TMEM59L的潜在药物.
未经证实:我们的研究揭示了TMEM59L在癌症中的预后价值以及基因组和免疫学特征,强调了TMEM59L作为预后癌症生物标志物和治疗靶标的潜力。
TMEM59L is a newly discovered transmembrane protein; its functions in cancer remain unknown. This study was designed to reveal the prognostic value and the functional role of
TMEM59L in cancer.
The gene expression profiles, methylation data, and corresponding clinical data of TMEM59L were retrieved from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression database. Survival analysis was employed to calculate the pan-cancer prognostic value of
TMEM59L. The correlation between TMEM59L expression and tumor immune microenvironment, as well as DNA methylation dynamics and genomic heterogeneity across cancers were assessed based on data from TCGA.
Our findings revealed that distinct differences of TMEM59L mRNA expression were observed in different cancer types and that higher
TMEM59L expression was observed in the advanced pathological stage and associated with worse prognosis in kidney renal papillary cell carcinoma, bladder urothelial carcinoma, colon adenocarcinoma, and kidney renal clear cell carcinoma. Pathway analysis indicated that TMEM59L exerted a key influence in cancer development and in immune- and cancer-associated pathways such as epithelial-mesenchymal transition and TGF-β signaling. Moreover, correlation analysis hinted at a negative correlation of TMEM59L expression with CD8 T cells, activated CD4 T cells, and several immunomodulators, including IDO1, TIGIT, PD-L1, CTLA-4, and BTLA in various cancers. Survival analysis indicated that the hypermethylation of TMEM59L gene was associated with longer survival times. A significant correlation was also observed between TMEM59L expression and immunophenoscore, homologous recombination deficiency, loss of heterozygosity, tumor stemness score, and neoantigens in various cancers. Importantly, we also identified numerous potential agents that may target
TMEM59L.
Our study revealed the prognostic value as well as the genomic and immunological characteristics of TMEM59L in cancers, highlighting the promising potential for TMEM59L as a prognostic cancer biomarker and a therapeutic target.